Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device
After a 1-hour administration with Sofusa, elevated lymph node concentrations have been measured beyond 72 hours.\nClinical study STI-SOFUSA-1003 is focused on patients with moderate to severe Rheumatoid Arthritis.
- After a 1-hour administration with Sofusa, elevated lymph node concentrations have been measured beyond 72 hours.\nClinical study STI-SOFUSA-1003 is focused on patients with moderate to severe Rheumatoid Arthritis.
- Patients eligible for this study are those who failed to develop an adequate response to Enbrel delivered through SC injections.
- While this is just the first patient in an open label study, this initial result is quite encouraging and in the right direction.
- \xe2\x80\x9cIn Collagen Induced Arthritic pre-clinical models, we have seen an improvement in lymphatic pumping when delivering Enbrel with Sofusa vs subcutaneous injections.